Misoprostol Prior to IUD Insertion in Nullipara

Launched by INSTITUTO MATERNO INFANTIL PROF. FERNANDO FIGUEIRA · Mar 30, 2018

Keywords

ClinConnect Summary

Nulligravidas women of reproductive age were submitted to IUD insertion between July 2009 and November 2011 at the Instituto de Medicina Integral Prof. Fernando Figueira in Recife, Pernambuco, Brazil. A total of 179 women were randomly allocated to two groups: 86 to use 400 µg of misoprostol vaginally four hours prior to IUD insertion and 93 to use placebo. Risk ratios (RR) were calculated as measures of relative risk, together with their 95% confidence intervals (95%CI). The number needed to treat (NNT) and the number needed to harm (NNH) were also calculated.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Nulliparous women
• • No chirurgical procedure in the cervix
• • Wish to use IUD as a contraceptive method
• Exclusion criteria are as follows:
• • Presence of active cervical infection visible upon speculum exam (purulent cervicits)
• • Pelvic Inflammatory Disease (PID) or other uterine infection diagnosed within the last 3 months (based on self-report or clinical documentation)
• • Pregnancy ending less than 6 weeks prior to enrollment in study
• • History of prior IUD placement
• • History of uterine cavity abnormality including Mullerian tract anomalies and leiomyomas distorting uterine cavity shape
• • History of uterine surgery
• • Allergy or intolerance to misoprostol or other prostaglandin
• • Undiagnosed abnormal vaginal bleeding
• • Malignancy of the genital tract
• • Allergy to any component of the IUD or Wilson's disease (for copper- containing IUDs)
• • Pre-procedure use of anesthesia or analgesia (including use of narcotics, benzodiazepines, or use of anesthetic beyond use at the tenaculum site)